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OBJECTIVES:To examine the association ofmissed diagnoseswith patient, ED, and
hospital characteristics using administrative dataMETHODS:We conducted a ret-
rospective analysis ofmissed stroke diagnosis using linked inpatient discharge and
ED visit records from the 2009 HCUP State Inpatient Databases (SID) and 2008 and
2009 HCUP State Emergency Department Databases (SEDD). This study was set in
inpatient facilities and emergency departments in nine states (CA, FL, HI, MA, MO,
NE, NY, SC, TN). We identified patients who were admitted for stroke and had a
“treat and release” ED visit in the prior 30 days for a benign headache or dizziness.
We excluded stroke admissions for patients under 18 years and for certain other
admissions (not occurring through the ED; occurring in facilities with fewer than
seven total stroke admissions during 2009; and with missing covariate values).
RESULTS: Males (OR0.75; p 0.001) and older individuals (compared to 18-44,
45-64: OR0.43; 65-74: OR0.28; 75: OR0.19; p.001) had lower odds, while
Blacks (OR1.17; p.03), Asian/Pacific Islanders (OR1.29; p0.03), and Hispanics
(OR1.30; p0.001) had higher odds of a missed stroke diagnosis. Medicare
(OR0.66; p .001) and Medicaid (OR0.70; p 0.001) patients had lower odds of a
missed diagnosis compared to privately-insured patients. Non-teaching hospitals
(OR1.45; p0.002) and hospitals with low volume (OR1.57; p0.008) had higher
odds of a missed diagnosis. CONCLUSIONS: Physicians in the ED who are evaluat-
ing patients with headache and dizziness might want to be more attuned to the
possibility of stroke in women, younger patients, and nonwhite patients.
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ANALYSIS OF GENERIC SIMVASTATIN AND ATORVASTATIN VERSUS BRANDED
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OBJECTIVES: Hyperlipidemic patients at risk of cardiovascular (CV) events who
receive simvastatin or atorvastatin as a first-line treatment may be less likely to
meet low-density lipoprotein cholesterol (LDL-C) goals and thus more likely to
experience CV events than patients who initiate on rosuvastatin. A deterministic
model was developed to estimate the budget impact over 3 years of initiating
high-risk patients in a hypothetical managed health care (MHC) plan on rosuvas-
tatin rather than simvastatin or atorvastatin. METHODS: Among 1,000,000 health
plan members aged 18 years, 1,000 patients (0.1%) were assumed to initiate
statins. The average baseline LDL-C level was 160mg/dL. Two scenarios weremod-
eled: in scenario 1 all patients were initiated on simvastatin or atorvastatin and
titrated to a higher dose, or switched to atorvastatin (if initiated on simvastatin) or
rosuvastatin; in scenario 2, 50% of the 530 high-risk patients – based on National
Cholesterol Education Program (NCEP) guidelines – were initiated on rosuvastatin.
Product labeling, clinical trial results, national prescription claims data, and pub-
lished literature were used to populate the model. Drug acquisition, administra-
tion, and event costs were considered. RESULTS: Over 3 years, 61 additional pa-
tients reached their LDL-C goal in scenario 2, comparedwith scenario 1 (770 vs. 709,
respectively), at an increased cost of $637,000 ($1,714,000 vs. $1,077,000, respec-
tively). The additional permember permonth (PMPM) cost of scenario 2 to theMHC
plan was $0.02. When the cost of managing CV events was accounted for, the
budget impact decreased to $634,000. CONCLUSIONS: Although the model has
some limitations, it highlights the value of appropriate prescribing of statins. Ini-
tiating high-risk hyperlipidemic patients on rosuvastatinmay increase the number
of patients reaching LDL-C goals (defined in NCEP guidelines) at a relativelymodest
increase in PMPM cost to a MHC plan, despite the low cost of generic statins.
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BUDGET IMPACT ANALYSIS OF INTRODUCING TICAGRELOR FOR THE
TREATMENT OF ACUTE CORONARY SYNDROME INTO THE PUBLIC HEALTH
CARE SECTOR OF HONG KONG
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OBJECTIVES: Ticagrelor (TG) is a new oral platelet inhibitor with improved thera-
peutic effect and safety profile than clopidogrel. Yet it is not listed in the public
hospital formulary of Hong Kong, hence suitable patients do not have general
access to it. A budget impact analysis would thus help provide evidence to assist
local budget holders in decision making processes. METHODS: A budget impact
model was built to allow assessment of the budgetary impact to the local health
care system from a government perspective if TG is introduced into the local mar-
ket. The scenarios adopted were world with andwithout TG. A hypothetical cohort
of 16,000 patients with acute coronary syndrome (ACS) was used as the population.
Proportion of ACS events was estimated using HK-specific values. Sources of drug
and DRGs costs were from the local public hospital authority as released in 2011.
Market shares of TG as compared to clopidogrel (branded) for world without and
with TG over a 5-year period were assumed to be 0% and 10-25% (with 5% incre-
ment/year) respectively. RESULTS: Over a 5-year period, the budget impact of
using TG was estimated to range from 1.18% (year-1) to 3.21% (year-5) if TG was
introduced. The actual extra cost per patient was estimated to range from
HKD423 (USD54, 1USD7.8HKD) in year-1 to HKD1,135 (USD146) in year-5. De-
terministic sensitivity analysis performed suggested that proportions of bleed-
ing between the 2 drugs and drug cost are the most influential variables. The
drug acqusition costs were partially offset by improved therapetic outcomes,
reduction in side effects and shortened hospital stay. CONCLUSIONS: Results of
the present budget impact analysis suggest that introducing TG into the market
of Hong Kong would only have minimal effect on the health care budget. Budget
holders should consider TG as an option to clopidogrel in view of its better
therapeutic effects and safety profile.
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OBJECTIVES:Todescribe and compare health resource utilization and related costs
of patients with chronic thromboembolic pulmonary hypertension (CTEPH) and
pulmonary arterial hypertension (PAH) in six European countries. METHODS: We
reviewed medical charts from patients diagnosed with CTEPH or PAH and treated
with PAH-specific therapy: Endothelin-receptor antagonists (ERA), prostacyclin an-
alogues (PA) or PDE5-inhibitors (PDEi). Data on demographic and clinical charac-
teristics, PAH-medication, and health resource utilization were retrospectively ab-
stracted from patients’ medical records at specialized PH treatment centers across
six European countries. Resource utilizationwas valued using country-specific unit
costs; descriptive statistical analyses were performed. RESULTS: Twenty one hos-
pitals documented 405 patients (120 in CTEPH and 285 in PAH). CTEPH patients
were older with a mean age of 67.5 12.1 years versus 55.3 15.6 years for PAH
patients. In the CTEPH group, 60% were female (PAH 74.4%) and both groups were
on average observed for 25.7months (SD 10.2). At baseline, 59.2% of CTEPH patients
received ERA (PAH 53%), 5.8% PA (PAH 5.0%), and 34.2% PDE5i (PAH 37.0%). CTEPH
patients experienced 1.8 2.2 hospitalizations per year accounting for 15.0 26.0
days in hospital, compared to PAH patients with 1.52.4 hospitalizations and 20.6
44.7 days, respectively. In both groups annual costs of PH medication was the
predominant cost factor averaging €37,346 23,183 in CTEPH and €38,840 29,072
in PAH, followed by hospitalizations (CTEPH €4,554 7,894, PAH €6,254 €13,571)
and concomitant medications (CTEPH €2,534  €2505, PAH €1,301  €1,514). Other
health care resource items only accounted for marginal additional costs in both
groups. CONCLUSIONS: These data show similar overall costs for patients with
PAHandCTEPH. Although, for CTEPHoff-label andwithout evidence from random-
ized trials, in both groups, PAH-specific medication was the predominant cost
factor. CTEPH patients tended to have higher costs for concomitant medication
whereas hospitalizations were more common in PAH.
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OBJECTIVES: Atrial Fibrillation (AF) greatly increases the risk of stroke. AF-related
stroke is associated with higher mortality, worse outcome and higher health care
cost, which is substantial for patients and society. Few studies, however, of the
costs of AF-related stroke were available in China. This study aimed to assess and
compare the hospital costs and length-of-stay in patients with AF and AF-related
stroke in China from payer’s perspective.METHODS:Data were extracted from the
BasicMedical Insurance Databases in 2010. 385 patientswere randomly selected by
stratified two-stage sampling. All information of patient demographic characters,
clinical and costs were collected for the analysis. The descriptive statistics was
used to describe patients’ demographic characters, the hospital stay and the hos-
pital costs. Univariate and multivariable analyses were also used in the data
analysis. RESULTS: Total 385 patients (mean age 70.6 years; 51.4% male) were
evaluated, 59.0% of patients with AF and 41.0% of patients with AF-related stroke.
The mean length-of-stay was 14.2 days (11.9 days AF and 17.5 days AF related
stroke; P 0.001); the mean total cost was 17630.42 (median: 9323.25, IQR: 5086.87-
20193.43): 17734.93 (median: 6891.92, IQR: 3898.78-20751.16) with AF and 17480.27
(median: 11975.32, IQR: 7863.3-19941.85)withAF-related stroke (P0.001). Themul-
tiple linear regressions showed that the hospital cost of AF-related stroke was 81%
higher than the hospital cost of AF. Patientswith basicmedical insurance for urban
employees had 39.6% higher costs than those with basic medical insurance for
urban residents (P0.001). Patients from tertiary hospitals had 97.8% higher costs
than those from primary hospitals; (P0.001) and patients frommunicipalities had
58.0% higher costs than those from prefecture-level cities; (P0.01).
CONCLUSIONS: Patients with AF-related stroke is associated with significantly
higher hospital costs compared with those with AF. It implied that stroke preven-
tion in AF may have potential cost savings.
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OBJECTIVES: The lack of data has presented a challenge to perform pharmacoeco-
nomic research in Asia. However, efforts have been made to make cost data avail-
able and this study presents newly available data from clinical costing databases in
Malaysia, Indonesia and the Philippines. The objective is to determine the length of
stay and treatment cost per episode of acutemyocardial infarction (MI).METHODS:
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Costs were estimated by the UNU-Casemix Group (UNU-CBG) system, a top-down
costing system developed by the United Nations University-International Institute
for Global Health and the National University of Malaysia. The above costing sys-
tem was used in the countries included in this study. An episode of inpatient care
for any condition was defined as all treatments provided by the hospital from the
time of admission until discharge. Length of stay and cost per acute episode of MI
were identified for analysis. Local currency costs were converted to 2012 US$.
RESULTS: The average length of stay for a mild, moderate and severe episode of
acute MI in Indonesia was 6.0, 8.3 and 13.8 days respectively, compared to 5.8, 7.5
and 9.2 days in Malaysia and 4.5, 7.1 and 10.2 days in the Philippines. The average
cost of mild, moderate and severe acute MI in these countries were US $1075, US
$1698 andUS $2450 in Indonesia, US $1264, US $1616 andUS $1999 inMalaysia, and
US $1220, US $1927 and US $2779 in the Philippines. CONCLUSIONS: Our results
show that length of stay and treatment cost for an episode of acute MI varied
between countries and increased with clinical severity. Differences may be due to
factors such as health systems and reimbursement mechanisms. In addition, we
found that the available cost data is useful for analysis of health care costs in South
East Asia.
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CROSS-COUNTRY COMPARISON OF TREATMENT COSTS WITH AMIODARONE
AND PROPAFENONE IN ARRHYTHMIA
Mehta P, Walker SA, Ando G
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OBJECTIVES: In light of the medicare savings debate in the US and AMNOG reform
in Germany, we aim to compare average branded factory price and average annual
cost of treatment for amiodarone and propafenone, the two most commonly pre-
scribed drugs for the treatment of arrhythmia, across 6 countries (EU top 5 and US).
METHODS:A quantitative analysis was performed using the average factory prices
for each branded active pharmaceutical ingredient (API) from IHS PharmaOnline
International (POLI) and average annual treatment costs from IHS World Markets
Cardiovascular and Metabolic service (WMCVM). We used dosing monographs to
calculate the total average dosing to accommodate for regional differences in cur-
rent treatmentmodalities. RESULTS: In the United States, the average price permg
for amiodarone is $0.006 and average annual cost of treatment is $2326. In the
Germany, UK, Italy, Spain and France, the average price per mg for amiodarone is
€0.025, £0.003, €0.003, €0.001 and €0.001, and average annual cost of treatment is
€9216, £1147, €973, €492, €365, respectively. In the United States, the average price
per mg for propafenone is $0.014 and average annual cost of treatment is $3480. In
the Italy, Spain, Germany, and United Kingdom, the average price per mg for
propafenone is €0.003, €0.001, €0.0009, £0.0005, and, and average annual cost of
treatment is €751, €380, €231, £124, respectively. CONCLUSIONS: That the price and
cost of amiodarone treatment is the highest in Germany is notable given the recent
launch of AMNOG. Amiodarone is one of themost common comparator for cardio-
metabolic drugs and its high price could allow for higher prices for newer market
entrants. The relative high price and cost of propafenone treatment in the United
States gives credence to proponents of health care savings who argue for system-
atic overhaul of drug prices.
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OBJECTIVES: To describe the real-world clinical complications associated with ve-
nous thromboembolism (VTE) and quantify the incremental direct all-cause and
disease-specific health care utilization and costs associated with VTE.METHODS:
Health insurance claims between January 2004 and December 2008 from the
IMPACTdatabasewere used. Adult patientswith an indexVTE diagnosis (deep vein
thrombosis [DVT], pulmonary embolism [PE], or both) were matched 1:1 with con-
trol patients without VTE. Each patient’s observation period began on the date of
the index VTE or corresponding date for controls and ended on the earlier of 1 year
after the study index date, the health plan disenrollment date, or December 31,
2008. The proportion of patients with recurrent VTE requiring hospitalization or
post-thrombotic syndrome (PTS)was calculated. All-cause incremental health care
costs associated with VTE and disease-specific costs related to VTE complications
were also reported. RESULTS: The VTE and no-VTE cohorts (16,969 subjects in each
group) were well matched for age, gender, comorbidities, and VTE risk factors. The
index VTE event was DVT, PE, or both in 12,711, 2473, and 1785 patients, respec-
tively. The risks of recurrent VTE requiring hospitalization and PTS during the
1-year follow-up period were 3.6% and 6.2%, respectively. Patients with VTE had
significantly higher average yearly all-cause costs compared to no-VTE patients
(mean [SD]: $33,531 [$70,393] versus $17,590 [$42,011], cost difference$15,941; 95%
CI14,819–17,012). Disease-specific health care costs related to VTE complications
represented 18.3% ($2913 of $15,941) of the all-cause cost difference between the
two groups. CONCLUSIONS: In this large matched-cohort study, VTE was associ-
ated with a 3.6% risk of hospitalization due to recurrence and a 6.2% risk of PTS at
1 year. VTE was also associated with significant health care cost burden—disease-
specific costs related to VTE complications represented nearly one-fifth of the in-
cremental all-cause costs associated with VTE.
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OBJECTIVES: To estimate the 1-year direct and indirect costs of ischemic stroke in
Chinese patients with atrial fibrillation (AF).METHODS:A cost-of-illness studywas
conducted through hospital chart review and a patient follow up survey. Costs
were estimated from the societal perspective. Three hundred hospital charts from
12 tier-3 hospitals and 6 tier-2 hospitals in 6 cities across China were randomly
selected and reviewed for cost of stroke during hospitalization from patients dis-
charged from January, 2009 to December, 2010 (discharge diagnosis of both, isch-
emic stroke and AF). Of those, 50 patients were followed up to collect the long-term
direct and indirect costs related to ischemic stroke in the year following discharge.
RESULTS:We report here results from two hospitals (N30): patients had a mean
age of 75 years and mean length of stay of 16 days (95%CI [14, 19]). Females
accounted for 43%. The mean time interval between stroke onset and hospitaliza-
tion was 24 hours (95%CI [14, 33]). The cohort scored on average 3 points (95%CI
[2, 4]) on the CHA2DS2-VASc, indicating a high risk of stroke considering patient
demographics and disease history. Average total 1-year costs of stroke manage-
mentwere estimated at 19,560.01 RMB (2010 costs; 4951.90US$), almost all ofwhich
was attributable to direct costs. Costs of inpatient care dominated direct costs,
representing 90.3% of the total direct costs. Average total costs during hospitaliza-
tion were estimated at 17,659.31 RMB (95%CI [13,538.39, 21,780.23]), 62.5% of
which was attributable to medication. CONCLUSIONS: The findings indicate that
ischemic stroke among AF patients are associated with high direct costs, imposing
a considerable burden on society. Hospital costs are the predominant contributor,
consistent with the current pattern of care in China, where patient care is usually
provided via hospitals.
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OBJECTIVES: To develop United States (US) cost model estimates for venous
thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary
embolism (PE). Total US costs were calculated as well as hospital-acquired, “pre-
ventable”, and indirect VTE costs.METHODS:A literature reviewwas performed to
determine VTE incidences, morbidity probabilities, case-fatality rates, and direct
medical and indirect costs. Indirect costs were derived from present value of life-
time earnings (PVLE) due to premature death. Two decision trees mapping PE and
DVT outcomes were developed, and cost models were constructed in Microsoft
Excel. The decision trees first contain primary VTE characteristics and outcomes:
hospital- or community-acquired; fatal versus non-fatal; readmission/recurrence
versus none; and instant versus non-instant death. Initially surviving patients are
at risk for associated morbidities: minor bleed; major bleed; heparin induced
thrombocytopenia; chronic thromboembolic pulmonary hypertension; post-
thrombotic syndrome; and resolution or no resolution of symptoms or death. The
average patient’s cost, the sum of each decision tree pathway’s probability-
weighted cost, weremultiplied by low and high annual PE and DVT incident events
to determine total cost ranges. All costs were adjusted to 2011 US dollars. Two
multi-way sensitivity analyses were conducted: one analysis has higher probabil-
ities and costs; the second introduces long term attack rates (LTAR), pooled inci-
dent and recurrent events, into the baseline and first multi-way sensitivity analy-
ses with only low VTE incidences. RESULTS: Annual US total base case (LTAR
sensitivity analysis), hospital-acquired, preventable, and indirect VTE costs range
from$13.4-27.0 ($15.3-34.3) billion, $8.9-18.0 ($10.2-25.3) billion, $4.5-14.0 ($5.1-12.7)
billion, and $4.5-9.8 ($5.6-11.7) billion, respectively. PE comprises the majority of
VTE costs. Indirect costs due to PVLE represent at least 33% of total VTE costs.
CONCLUSIONS: The United States could avoid substantial costs, morbidity and
mortality if effective VTE prophylactic strategies were implemented. This attain-
able goal would contribute to important health care reform.
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DETERMINANTS OF PHARMACEUTICAL EXPENDITURES FOR PATIENTS WITH
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Cai B
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OBJECTIVES: Using longitudinal data, this study examined the determinants of
pharmaceutical expenditures for patients with hypertension, and the impact of
lifestyle andmarriage status changes on pharmaceutical expenditures.METHODS:
The longitudinal household components and the prescribedmedicine data ofMed-
ical Expenditure Panel Survey (MEPS) for year 2008 and 2009 were employed. Five
rounds of the survey were conducted for Panel 13 households between years 2008
and 2009. Only round 3 and round 5 surveys were used for this work because BMI
values were only included in these two rounds. I included individuals older than 18
years, not pregnant, with hypertension but no other comorbid conditions, andwho
had obtained a prescription for antihypertensive agents for essential hypertension
(ICD-9 code 401). The final panel data contained 1814 observations, among which
average agewas 53.65 years (SD13.49), the average age at the time of hypertension
diagnosis was 44.22 (SD13.43) years, 49.91% (SD0.50) were male. Ordinary Least
Square and Mixed Effect Model were employed to investigate the determinants of
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